Consistent with this notion, the activation markers CD38, HLA-DR, and Ki-67 expressed on Mtb-specific CD4+ T cells in TB patients reverted to healthy or latent TB infection phenotype at the end of treatment, supporting the idea that phenotypic changes of Mtb-specific T cells are potential markers for monitoring treatment efficacy [14,15,16]. The gene discussed is CD38; the disease is tuberculosis.